NCT00036764View on ClinicalTrials.gov

BMS-247550 in Treating Patients With Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

August 31, 2004

Conditions
Recurrent MelanomaStage IV Melanoma
Interventions
DRUG

ixabepilone

Given IV

OTHER

pharmacogenomic studies

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

10016-4760

New York University Clinical Cancer Center, New York

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00036764 - BMS-247550 in Treating Patients With Stage IV Melanoma | Biotech Hunter | Biotech Hunter